Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00263-1/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=276355044&_hsenc=p2ANqtz-8xak_cn9XRs-eP1OlZkJZbQf55H7iguvtZsXsY3L6pnSwYCOjz_UHyHlvI9A4mF8RAj1jnnnNrxAkUcymcp4Fu2-KFFg&utm_content=276317812&utm_source=hs_email